Clinical trials: Diabetic Mellitus
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
This is a phase II/III seamless design, randomized, double-blind, paralleled-group, placebo-controlled study to evaluate the efficacy and safety of Xianglei Tangzu Gao for the treatment of Wagner grade II diabetic foot ulcers.
- Trial name
- NCT06531512
- Testing
- Xianglei Tangzu Gao, Vehicle Cream
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Oneness Biotech Co., Ltd.
Diabetic Foot, Diabetic Foot Ulcer
Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200
Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Diabetic Foot Ulcer Neuropathic
- Trial name
- NCT06003530
- Testing
- hOMSC200
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Cytora Ltd.
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy
Efficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy
This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy…
- Conditions
- Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain
- Trial name
- ABBT DPN (NCT07250828)
- Testing
- BurstDR Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- TriCity Research Center
Diabetic Foot Ulcer
A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs
This study is a prospective comparative study to determine if an Iodine Gel (Iodosorb◊) is better than standard dressing (Solosite◊ gel) in disruption of biofilm (small microorganism bacteria similar to plaque on teeth) on the…
- Trial name
- NCT02181621
- Testing
- Iodosorb, Solosite gel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Smith & Nephew, Inc.
Foot Ulcer, Diabetic, Diabetic Foot
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
The purpose of this study is to assess if the experimental drug, DSC127, is safe, how well it can be tolerated, and how different doses effect the healing of the chronic foot ulcers in diabetic subjects.
- Trial name
- NCT00796744
- Testing
- NorLeu3-A(1-7) in a gel formulation
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- US Biotest, Inc.
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Diabetic Neuropathy
Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy
The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo.
- Trial name
- NCT00568035
- Testing
- QR-333
- Where
- 19 sites in United States
- Volunteers
- 140 people
- Sponsor
- Quigley Pharma, Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the efficacy of metformin and repaglinide used alone or combined administered as initial treatment in subjects with type 2 diabetes in which diet and exercise…
- Trial name
- NCT01465152
- Testing
- metformin, repaglinide
- Where
- 18 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patients with diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00871416
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 12 mm
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Non-healing Wound, Diabetic Foot
AMNIODERM+ Medical Device Clinical Study
This is retrospectively-prospective clinical trial with medical device AMNIODERM+ intended for the non-healing wounds. Retrospective data will contain information about the subject's history and wound treatment by SoC.
- Trial name
- AMNIODERM+ (NCT06442865)
- Testing
- AMNIODERM+
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- BioHealing s.r.o.
Type II Diabetes Mellitus
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
- Trial name
- NCT00997152
- Testing
- JTT-654
- Where
- 42 sites in United States
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Diabetic Neuropathies, Pain
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT00283842
- Testing
- DVS SR
- Where
- 51 sites in United States
- Volunteers
- 408 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetic Foot Ulcers
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
- Trial name
- NCT00563394
- Testing
- ofloxacin, MSI-78
- Where
- United States
- Volunteers
- 584 people
- Sponsor
- Abeona Therapeutics, Inc
Painful Diabetic Peripheral Neuropathy
A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).
Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective.
- Trial name
- NCT01726413
- Testing
- GRC 17356
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 138 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Diabetic Foot, Diabetic Foot Ulcer
Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
The study will evaluate the safety and performance of Symphony™ versus Standard of Care (SOC) in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer
- Trial name
- NCT06035536
- Testing
- Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol
- Where
- 11 sites in United States
- Volunteers
- 143 people
- Sponsor
- Aroa Biosurgery Limited
Diabetes, Diabetes Mellitus, Type 1
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes
This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240.
- Trial name
- NCT01486381
- Testing
- biphasic insulin aspart 30
- Where
- 2 sites in South Africa
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients
This is a monocentric, randomized, single-blind and controlled study with a parallel design (2 arms). The research hypothesis is that the diet high in Slow Digestible Starch (SDS) content (H-SDS) will lower the daylong glycemic…
- Trial name
- NCT03847701
- Testing
- Balanced diet high in Slowly Digestible Starch, Balanced diet low in Slowly Digestible Starch
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Mondelēz International, Inc.
Diabetic Foot Ulcers
Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers
The purpose of this study is to compare the wound closure outcomes of subjects receiving diabetic foot ulcer treatment with and without the use of Biovance®.
- Trial name
- NCT02506452
- Testing
- Biovance®, Standard of Care, Diabetic Foot Ulcers
- Where
- 10 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliqua BioMedical, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.